B-cell lymphoma diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
Adnan Ezici (talk | contribs) No edit summary |
Adnan Ezici (talk | contribs) No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 3: | Line 3: | ||
{{CMG}} ; {{AE}} {{Adnan Ezici}} | {{CMG}} ; {{AE}} {{Adnan Ezici}} | ||
==Overview== | ==Overview== | ||
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. Excisional [[lymph node biopsy]] is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma. | |||
==Diagnostic Study of Choice== | ==Diagnostic Study of Choice== | ||
=== Study of choice === | === Study of choice === | ||
B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. | B-cell lymphomas include both [[Hodgkin's lymphoma]]s and most [[Non-Hodgkin lymphomas]]. | ||
*Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><ref name="pmid28395545">{{cite journal |vauthors=Jiang M, Bennani NN, Feldman AL |title=Lymphoma classification update: B-cell non-Hodgkin lymphomas |journal=Expert Rev Hematol |volume=10 |issue=5 |pages=405–415 |date=May 2017 |pmid=28395545 |doi=10.1080/17474086.2017.1318053 |url=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref> | *Excisional [[lymph node biopsy]] is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.<ref name="pmid32703953">{{cite journal |vauthors=Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL |title=Hodgkin lymphoma |journal=Nat Rev Dis Primers |volume=6 |issue=1 |pages=61 |date=July 2020 |pmid=32703953 |doi=10.1038/s41572-020-0189-6 |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref><ref name="pmid28395545">{{cite journal |vauthors=Jiang M, Bennani NN, Feldman AL |title=Lymphoma classification update: B-cell non-Hodgkin lymphomas |journal=Expert Rev Hematol |volume=10 |issue=5 |pages=405–415 |date=May 2017 |pmid=28395545 |doi=10.1080/17474086.2017.1318053 |url=}}</ref><ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref> | ||
*Fine-needle aspiration or core-needle biopsy specimens are usually | *[[Fine-needle aspiration]] or core-needle biopsy specimens are usually insufficient because these methods have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes. | ||
*Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with immunohistochemistry to determine the subtype. | *Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with [[immunohistochemistry]] to determine the subtype. | ||
===== Diagnostic results ===== | ===== Diagnostic results ===== | ||
*The following findings on | *The following findings on pathological evaluation are confirmatory for Hodgkin's lypmhoma:<ref name="pmid29763144">{{cite journal |vauthors=Kaseb H, Babiker HM |title= |journal= |volume= |issue= |pages= |date= |pmid=29763144 |doi= |url=}}</ref> | ||
**Reed-Sternberg cells (RS) | **[[Reed-Sternberg cells]] (RS) | ||
**Lymphocyte predominant cells (LP) | **Lymphocyte predominant cells (LP) | ||
*The following findings on immunophenotypic analysis are confirmatory for the following types of non-Hodgkin's lypmhoma:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref> | *The following findings on immunophenotypic analysis are confirmatory for the following types of [[non-Hodgkin's lypmhoma]]:<ref name="pmid32644754">{{cite journal |vauthors=Sapkota S, Shaikh H |title= |journal= |volume= |issue= |pages= |date= |pmid=32644754 |doi= |url=}}</ref><ref name="pmid27466666">{{cite journal |vauthors= |title= |journal= |volume= |issue= |pages= |date= |pmid=27466666 |doi= |url=}}</ref> | ||
**MYC-IGH rearrangement detected by [[FISH]] in the presence of a [[BCL2]] negative germinal centres phenotype is definitive for | **MYC-IGH rearrangement detected by [[FISH]] in the presence of a [[BCL2]] negative germinal centres phenotype is definitive for diagnosis of [[Burkitt lymphoma]]. | ||
**A disrupted structure of [[follicle center]] by sheets of large cells which are positive for pan-B-cell antigens (e.g., [[CD20]], CD79a) is definitive for | **A disrupted structure of [[follicle center]] by sheets of large cells which are positive for pan-B-cell antigens (e.g., [[CD20]], CD79a) is definitive for diagnosis of [[diffuse large B-cell lymphoma]] (DLBCL).<ref name="pmid30859597">{{cite journal |vauthors=Liu Y, Barta SK |title=Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment |journal=Am J Hematol |volume=94 |issue=5 |pages=604–616 |date=May 2019 |pmid=30859597 |doi=10.1002/ajh.25460 |url=}}</ref> | ||
**A [[chromosomal translocation]] t(11:14) is definitive for | **A [[chromosomal translocation]] t(11:14) is definitive for diagnosis of [[mantle cell lymphoma]].<ref name="pmid28699667">{{cite journal |vauthors=Vose JM |title=Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management |journal=Am J Hematol |volume=92 |issue=8 |pages=806–813 |date=August 2017 |pmid=28699667 |doi=10.1002/ajh.24797 |url=}}</ref> | ||
Latest revision as of 16:50, 6 May 2022
|
B-cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
B-cell lymphoma diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of B-cell lymphoma diagnostic study of choice |
|
Risk calculators and risk factors for B-cell lymphoma diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Adnan Ezici, M.D[2]
Overview
B-cell lymphomas include both Hodgkin's lymphomas and most Non-Hodgkin lymphomas. Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.
Diagnostic Study of Choice
Study of choice
B-cell lymphomas include both Hodgkin's lymphomas and most Non-Hodgkin lymphomas.
- Excisional lymph node biopsy is the gold standard test for the diagnosis of B-cell lymphomas. It is the preferred method to protect the architecture of lymph nodes, which is crucial for pathological evaluation and classification of lymphoma.[1][2][3][4]
- Fine-needle aspiration or core-needle biopsy specimens are usually insufficient because these methods have a low ratio of malignant cells and they do not sufficiently preserve the architecture of lymph nodes.
- Diagnostic studies of B-cell lymphomas include light microscopic evaluation of pathologic sample, as well as an immunophenotypic analysis with immunohistochemistry to determine the subtype.
Diagnostic results
- The following findings on pathological evaluation are confirmatory for Hodgkin's lypmhoma:[4]
- Reed-Sternberg cells (RS)
- Lymphocyte predominant cells (LP)
- The following findings on immunophenotypic analysis are confirmatory for the following types of non-Hodgkin's lypmhoma:[5][2]
- MYC-IGH rearrangement detected by FISH in the presence of a BCL2 negative germinal centres phenotype is definitive for diagnosis of Burkitt lymphoma.
- A disrupted structure of follicle center by sheets of large cells which are positive for pan-B-cell antigens (e.g., CD20, CD79a) is definitive for diagnosis of diffuse large B-cell lymphoma (DLBCL).[6]
- A chromosomal translocation t(11:14) is definitive for diagnosis of mantle cell lymphoma.[7]
References
- ↑ Connors JM, Cozen W, Steidl C, Carbone A, Hoppe RT, Flechtner HH, Bartlett NL (July 2020). "Hodgkin lymphoma". Nat Rev Dis Primers. 6 (1): 61. doi:10.1038/s41572-020-0189-6. PMID 32703953 Check
|pmid=value (help). - ↑ 2.0 2.1 . PMID 27466666. Missing or empty
|title=(help) - ↑ Jiang M, Bennani NN, Feldman AL (May 2017). "Lymphoma classification update: B-cell non-Hodgkin lymphomas". Expert Rev Hematol. 10 (5): 405–415. doi:10.1080/17474086.2017.1318053. PMID 28395545.
- ↑ 4.0 4.1 Kaseb H, Babiker HM. PMID 29763144. Missing or empty
|title=(help) - ↑ Sapkota S, Shaikh H. PMID 32644754 Check
|pmid=value (help). Missing or empty|title=(help) - ↑ Liu Y, Barta SK (May 2019). "Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment". Am J Hematol. 94 (5): 604–616. doi:10.1002/ajh.25460. PMID 30859597.
- ↑ Vose JM (August 2017). "Mantle cell lymphoma: 2017 update on diagnosis, risk-stratification, and clinical management". Am J Hematol. 92 (8): 806–813. doi:10.1002/ajh.24797. PMID 28699667.